Related Experiment Video
Updated: Dec 15, 2025

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
A single-centre experience of intravenous thrombolysis for stroke in COVID-19 patients
Davide Sangalli1, Valeria Polonia2,3, Daniele Colombo2
1Unit of Neurology, "Alessandro Manzoni" Hospital - ASST Lecco, Via dell'Eremo 9/11, 23900, Lecco, Italy. d.sangalli@asst-lecco.it.
Insights
Intravenous thrombolysis for acute ischemic stroke in COVID-19 patients presents significant risks. This study highlights unpredictable complications and high mortality, questioning the risk-benefit balance of rt-PA in these cases.
Area of Science:
- Neurology
- Infectious Diseases
- Cardiovascular Medicine
Background:
- The Coronavirus Disease 2019 (COVID-19) pandemic created unprecedented challenges in managing acute ischemic stroke.
- The safety and efficacy of intravenous thrombolysis, particularly recombinant tissue plasminogen activator (rt-PA), in COVID-19 positive patients remain unclear.
Observation:
- This study details four cases of acute ischemic stroke in patients with confirmed COVID-19 who underwent intravenous thrombolysis.
- These patients exhibited unusual stroke features and experienced severe, unexpected complications post-treatment.
Findings:
- The administration of rt-PA in acute ischemic stroke patients with COVID-19 was associated with a very high overall mortality rate.
- The risk-benefit profile of intravenous thrombolysis in this specific patient population appears unfavorable due to unpredictable adverse events.
Implications:
- These findings suggest a need for cautious consideration of intravenous thrombolysis in acute ischemic stroke patients who are also positive for COVID-19.
- Further research is warranted to understand the pathophysiology and to establish optimal management strategies for acute ischemic stroke in the context of COVID-19 infection.
Abstract:
The sudden worldwide outbreak of Coronavirus Disease 2019 (COVID-19) has certainly provided new challenges in the management of acute ischaemic stroke, and the risk-benefit ratio of intravenous thrombolysis in COVID-19 positive patients is not well known. We describe four COVID-19 patients treated with intravenous thrombolysis for acute ischaemic stroke. Although rt-PA administration is the main therapeutic strategy, our patients experienced unpredictable complications and showed atypical features: the overall mortality was very high. In conclusion, in this article, we provide information about these cases and discuss the possible explanation behind this trend.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Venous Thrombosis I: Introduction

